Effective combination therapy of bortezomib and dexamethasone for a plasma cell leukemia patient with multiple osteolytic lesions and extramedullary involvement

Università degli Studi di Bari Aldo Moro, Bari, Apulia, Italy
Acta Oncologica (Impact Factor: 3). 02/2007; 46(2):262-4. DOI: 10.1080/02841860600897975
Source: PubMed
Download full-text


Available from: Mario Delia, Jan 29, 2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: These studies, carried out on the pseudospark discharge, show its high ability to open a circuit at zero current. The interesting results are linked to the diffuse discharge mode, and allow avoidance of the development of anodic spots at high peak current above 40 kA. In these experiments, after a pulse current of 18 kA and 225 μs duration, the rate of reapplied voltage is 18 kV/μs and the peak of withstand voltage is 18 kV. This ability depends strongly on the electrode conditioning. The authors obtained the best results with a number of shots up to 200 and a rate current lower than 210<sup>8</sup> A/s. They believe that the values of the rate of current at zero current (conduction phase) have a great influence on the opening switch performance. They investigate other characteristics, such as the dimensions of the cavities, the hole diameter, the gap and the pressure, in order to increase performance. A CCD camera allows investigation of the conduction phase and the recovery phase before and after zero current crossing
    No preview · Conference Paper · Aug 1996
  • [Show abstract] [Hide abstract]
    ABSTRACT: The most aggressive and rare manifestation of multiple myeloma is plasma cell leukaemia (PCL). While secondary form of PCL represents those heavily pretreated cases when leukaemic transformation develops terminally after intensive chemotherapy in patients with multiple myeloma, primary cases are characterized by leukaemic symptoms present at diagnosis. The secondary form has a rapid progression. The management of PCL is still unsolved. The authors present a case of a patient with non-secretory multiple myeloma who had developed plasma cell leukaemia after peripheral stem cell transplantation. PAD (bortezomib, doxorubicin, dexamethasone) treatment resulted in complete remission and 9-month survival of the patient. Previous case reports in the literature and our experience have revealed PAD protocol to be well tolerated and effective in PCL. Combination of PAD treatment with autologous and/or allogenic stem cell transplantation might further improve patients' outcome.
    No preview · Article · Nov 2008 · Orvosi Hetilap
  • Source

    Preview · Article · May 2010 · Haematologica
Show more